As a company with an important position in the pharmaceutical and architectural steel structure fields, Huasun Technology Group Inc., Ltd. (stock code: 000790) will receive significant market attention for its business activities in 2023. In the past year, Huasun Technology has faced multiple challenges, such as policy adjustments in the pharmaceutical industry, intensified market competition, and rising raw material costs. However, it is actively seeking transformation and breakthroughs, striving to find new growth points in the change.

From the asset-liability data perspective, Huasun Technology's total assets increased from 1.677 billion yuan in 2022 to 2.133 billion yuan in 2023, an increase of 27.22%, showing an expansion of the company's scale. The total liabilities also increased from 672 million yuan to 1.057 billion yuan, and the asset-liability ratio increased from 40.04% to 49.55%, indicating that the company has increased its financial leverage in order to expand its operating scale, but also correspondingly increased its financial risk. The significant increase in goodwill, from 56.06 million yuan to 107 million yuan, reflects the company's strategic layout of outward expansion through mergers and acquisitions.

In terms of profit data, although the company's revenue increased from 873 million yuan to 1.003 billion yuan, an increase of 14.92%, the net income attributable to shareholders of the listed company decreased from 4.122 million yuan to 2.766 million yuan, a decrease of 32.89%. This change is mainly due to increased R&D investment, rising financing costs for new businesses, and non-recurring losses from subsidiary relocation. In addition, both gross profit margin and net profit margin have declined, indicating that cost control and profitability are under pressure.

Cash flow data also reveals some issues. Although the net cash flow from operating activities decreased significantly from 156 million yuan to 4.741 million yuan, a decrease of 69.58%, this may indicate that the company's cash recovery ability in operating activities has weakened. This is a risk point that cannot be ignored for the capital-intensive pharmaceutical and architectural steel structure industries.

Overall, Huasun Technology faces significant challenges in 2023. Changes in asset-liability situation, profit and cash flow all reflect that the company needs to face problems such as cost control, declining profitability, and cash flow tension while expanding. In the future, Huasun Technology needs to strengthen internal management, optimize cost structure, improve profitability and cash flow level, in order to achieve sustainable development while maintaining growth.